Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Bloom Energy | Applied Digital | Moderna | |
|---|---|---|---|
| Moat rating | narrow FY2025 10-K (Item 1, filed 2026-02-09): a proprietary solid-oxide platform protected by 380 active U.S. utility patents plus 183 pending, with speed-to-power the company says can deliver onsite power 'within approximately 90 days' — real but contested advantages: the same 10-K's Item 1A calls distributed generation and hydrogen 'still emerging markets' whose acceptance is uncertain, and revenue concentration was 43%/13%/12% across three customers in FY2025 (sec.gov/Archives/edgar/data/1664703/000162828026006516/be-20251231.htm). | none The FY2026 10-K (filed 2026-07-29) shows contracted revenue, not a demonstrated competitive edge. About 1,410 MW is leased under 15-year take-or-pay, non-cancellable base terms worth about $36.2 billion, but only about 100 MW of the roughly 1.5 GW that is contracted and either operating or under construction was operating and earning revenue at May 31, 2026, and Item 1A says "lessees may have the right to terminate applicable leases if there are significant delays in construction." Item 1A also concedes "We do not have the resources to compete with larger providers of similar products or services at this time," and the Competition section names 13 power-advantaged developers the company competes with. Signed leases give revenue visibility, but the filing does not show a durable advantage. | narrow The FY2025 10-K supports a real but bounded advantage. The Competition section says the company believes "mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage," and the Intellectual Property section backs that with more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed outside the U.S., 485 pending applications, and latest-to-expire granted patents on all three approved products projected to 2041 in the U.S. and 2036 in Europe. Item 1A cuts the band down from wide: it opens the competition risk with "The vaccine market, and pharmaceutical market more generally, is intensely competitive," says Moderna "ha[s] been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026," that in RSV it "entered a market already occupied by two larger competitors," and that rivals "have exploited and may in the future exploit their greater size, infrastructure, resources and experience." The same section reports net losses of $2.8 billion in 2025 and $3.6 billion in 2024 against 2025 total revenue of $1.9 billion. |
| Moat type | intangibles ip The FY2025 10-K states 'Intellectual property is an essential differentiator for our business' and details 380 active U.S. utility patents, 252 active international patents, trade secrets around cell printing, and a purpose-built copy-exact Newark manufacturing facility — the moat rests on proprietary solid-oxide technology and manufacturing know-how, not network effects or locked-in customers (Item 1, Intellectual Property / Manufacturing Facilities). | none The 10-K claims three advantages: power-advantaged sites (it believes securing power and interconnection ahead of demand is 'the principal constraint on new HPC capacity and a core differentiator for us from many of our competitors'), a standardized 'franchise-style' design, and hyperscaler master service and master telecom service agreements 'that are difficult to obtain.' The filing does not show any of them to be durable. Its Competition section says competition 'centers on securing and developing sites with access to large-scale, reliable, and cost-competitive power and interconnection' and names 13 power-advantaged developers going after the same leases, and Item 1A concedes it lacks the resources to compete with larger providers. Signed leases are take-or-pay and non-cancellable, so a tenant leaving for convenience owes 'the full remaining contractual value,' but that is contractual lock-in on each lease rather than a moat source, so no moat type is assigned. | intangibles ip The filing locates the advantage in a patent and know-how estate, not in customer lock-in or cost. Intellectual Property describes "an expansive, multi-layered IP estate" whose platform claims cover mRNA chemistry, sequence optimization, engineering elements, LNP delivery systems and "innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product," alongside "substantial proprietary know-how associated with related manufacturing processes" and a trademark portfolio of at least 1,400 registrations. Nothing in the filing claims switching costs or a cost advantage; Item 1A says the opposite, that competitors leverage "larger supply chains and greater purchasing power." |
| Leadership | clear leader Scoped to fuel-cell-based onsite power for datacenters: Energy Changemakers (2026-07-04) positions Bloom as the market leader in fuel-cell deployment for AI datacenters — Brookfield framework expanded $5B→$25B, Oracle up to 2.8 GW, Equinix 100+ MW across 19 US datacenters, AEP gigawatt-scale — with FuelCell Energy the named challenger at smaller aggregate scale (~450/380/360 MW deals). In onsite power broadly (vs. turbines and engines) Bloom is one option among several (energychangemakers.com/fuel-cells-gain-ground-in-data-centers/). | behind The 10-K makes no leadership claim and gives no ranking or share figure. Item 1A concedes "We do not have the resources to compete with larger providers of similar products or services at this time" and that some rivals have "substantially greater liquidity and financial resources than we do." Its Competition section places APLD against established operators (Digital Realty, Equinix), hyperscalers that build their own capacity, independent developers and 13 named power-advantaged developers (IREN, Cipher Digital, TeraWulf, Hut 8, Riot, CleanSpark, HIVE, Core Scientific, Bitdeer, Galaxy Digital, Fermi, Keel Infrastructure, MARA). | co leader The Business section opens with the company's own claim that "Moderna is a pioneer and leader in the field of mRNA medicine." The Competition section frames the commercial reality more narrowly as a contest against a small named set: "We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also compete against other vaccines, including Sanofi and Novavax's." It does not claim a rank anywhere, and it places Moderna behind in the other approved category: in RSV "we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date." |
| Pricing power | moderate Q2 2026 release: GAAP gross margin 33.4%, up 668 bps YoY, with 34.3% non-GAAP and raised FY26 guidance of ~34% non-GAAP gross margin — margin expansion during a supply-constrained turbine market suggests real but cyclical pricing leverage; the FY2025 10-K frames the core competition as grid electricity and combustion OEMs on cost, which caps pricing through the cycle (sec.gov/Archives/edgar/data/1664703/000162828026050150/ex991_q226financialresults.htm). | weak Item 1A says "Due to the limited number of hyperscalers, we expect that a limited number of customers will continue to account for a high percentage of our revenue for the foreseeable future," and that if customers' equipment usage declines or they discontinue use of its facilities, APLD "may be compelled to lower our lease prices in some instances or risk losing a significant customer." One customer was 59% of FY2026 revenue from continuing operations. Take-or-pay, non-cancellable terms protect contracted revenue over the base term, and Note 19 reports a $39.1M HPC Hosting segment profit on $385.3M of segment revenue in FY2026, but those terms are agreed with a small group of concentrated buyers. | weak Item 1A states that "certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices," and that "in some instances, our competitors have been able to offer more attractive terms than we can, and they may continue to do so in the future." On the flu candidate it says that in a well-developed market Moderna "may need to offer more favorable terms to gain market share (which we may be unable to do), which may negatively impact our profitability." The Commercial section adds that its markets are "characterized, particularly in the U.S. (our largest market), by a fragmented end customer base, unpredictability in orders and seasonality of deliveries." |
| Summary | Bloom's edge is a single solid-oxide platform — 'cell printing, stack assemblies, and column configurations' — that serves both the Energy Server and the Bloom Electrolyzer, protected by 380 active U.S. patents and decades of materials know-how (FY2025 10-K, Item 1). Against its practical competition — grid power, gas reciprocating engines, small gas turbines, and other fuel-cell chemistries (PEM/MCFC/PAFC) — the 10-K claims higher efficiency, no combustion, 99.9% fleet availability on post-2020 non-redundant installs, and deployment in weeks-to-months while turbine OEMs are supply-constrained. That time-to-power window is currently being monetized in AI datacenters: the Q2 2026 release (2026-07-28) reported record revenue of $1,065.4M (+165.5% YoY) and management said all major U.S. hyperscalers have 'validated and approved' Bloom, calling it 'a standard for AI onsite power.' The moat is rated narrow, not wide: the 10-K's own risk factors stress that distributed generation is an emerging market with uncertain acceptance, three customers were 43%/13%/12% of FY2025 revenue, and industry coverage (Energy Changemakers, 2026-07-04) shows FuelCell Energy signing deals of comparable scale — the advantage is a technology-and-execution lead that rivals and turbine capacity additions can compress, not a structural lock. | Applied Digital designs, builds and operates purpose-built, liquid-cooled HPC data centers, which it calls 'AI factories', and leases the capacity to CoreWeave and investment-grade hyperscalers. At May 31, 2026 its 10-K lists five campuses (Polaris Forge 1-3 and Delta Forge 1-2) with about 1,410 MW contracted under roughly 15-year take-or-pay, non-cancellable leases worth about $36.2 billion over the base terms. The filing claims three sources of advantage: it controls power-advantaged sites, it uses a standardized 'franchise-style' design built to deliver about 150 MW in about 14 to 18 months, and it holds hyperscaler master agreements that are 'difficult to obtain.' The same document shows how early the company is. About 100 MW was operating and earning revenue. One customer was 59% of FY2026 revenue from continuing operations. It competes with Digital Realty, Equinix, hyperscalers that build their own capacity and 13 named power-advantaged developers, and it concedes that it lacks the resources to compete with larger providers. Signed leases give long-dated revenue visibility, but the filing does not show a durable competitive advantage. | Moderna's 10-K rests its competitive case on the mRNA platform and the IP wrapped around it: the company states it believes its capabilities "across mRNA technology, drug discovery, development and manufacturing" differentiate it, and reports more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed abroad, 485 pending applications, and granted patents on Spikevax, mNEXSPIKE and mRESVIA projected to expire in 2041 (U.S.) and 2036 (Europe), plus trade secrets and manufacturing know-how it calls substantial. The filing is equally direct about the limits: the principal COVID rival's vaccine "is also based on mRNA technology"; a competitor's European Commission contract keeps Moderna out of many European COVID markets until year-end 2026; RSV sales are "minimal to date" behind Pfizer and GSK; and the risk factors warn that "the mRNA medicines field is growing rapidly, with increased competitive pressure from large and more established pharmaceutical companies." What is durable is science and plant rather than commercial position: Moderna bought and operates the Norwood (MTC) campus, completed a Marlborough site purpose-built for intismeran autogene that began shipping patient batches in September 2025, and runs UK, Canada and Australia facilities that were fully licensed in 2025, each government having entered a multi-year commitment to purchase mRNA products from the company. |
| Chain position | Onsite prime-power supplier to AI infrastructure: per the FY2025 10-K, AEP is procuring up to 1 GW of Bloom fuel cells for AI datacenter loads, Brookfield established a financing framework (up to $5.0B over five years at signing, per the 10-K) housed in an AI Infrastructure Fund, and SK ecoplant (a ~2.5% Class A holder) distributes and co-assembles in Korea; the Q2 2026 release adds that all major U.S. hyperscalers plus over a dozen neoclouds, AI labs, and colocation operators have approved Bloom's systems. | Developer and landlord of power-advantaged, liquid-cooled AI data-center capacity, leased long-term to CoreWeave and investment-grade hyperscalers. | A vertically integrated mRNA developer-manufacturer that sits between upstream licensors and government or retail buyers: it in-licenses the Penn modified-mRNA patents non-exclusively through Cellscript and mRNA RiboTherapeutics at low-single-digit royalties and NIAID's prefusion coronavirus spike and prefusion RSV F patents, manufactures drug substance at the owned Norwood MTC campus and individualized therapy at Marlborough, runs Moderna-built plants in the UK, Canada and Australia against multi-year government purchase commitments, and relies on CMOs for critical raw material production and fill-finish. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.20 at weight 0.20 · swarm bullish Editorial prior, not backtested. | -0.20 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.05 at weight 0.20 · swarm bearish Editorial prior, not backtested. |